GILD GILEAD SCIENCES, INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 882095 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.5%
TTM net income YoY-147.6%
TTM EPS YoY-148.5%
Revenue 3-yr CAGR4.2%
Net income 3-yr CAGR—
Margins
Gross margin79.9%
Operating margin-7.6%
Net margin-12.5%
FCF margin44.5%
EBITDA margin-6.3%
Returns
ROE-22.3%
ROA-7.0%
ROIC (approx.)-5.2%
Asset turnover0.56x
Leverage & solvency
Liabilities / assets74.8%
Debt / equity2.01x
Current ratio1.38x
Interest coverage-2.34x
Cash quality & payout
Operating cash flow / net income-3.75x
Accruals ratio-33.4%
Payout ratio—
Capex / revenue2.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $8.30B | $7.80B | $6.96B | $7.92B | $7.77B | $7.08B | $6.67B | $7.57B |
| Cost of revenue | $1.57B | $1.58B | $1.45B | $1.62B | $1.57B | $1.50B | $1.54B | $1.58B |
| Gross profit | $6.73B | $6.22B | $5.51B | $6.30B | $6.20B | $5.58B | $5.13B | $5.99B |
| R&D expense | $1.61B | $1.76B | $1.37B | $1.58B | $1.35B | $1.49B | $1.38B | $1.64B |
| SG&A expense | $1.64B | $1.92B | $1.45B | $1.79B | $1.36B | $1.36B | $1.26B | $1.91B |
| Operating income | $3.46B | -$10.39B | $2.59B | $1.98B | $3.33B | $2.47B | $2.24B | $2.45B |
| Interest expense | $269.00M | $247.00M | $240.00M | $255.00M | $256.00M | $254.00M | $260.00M | $249.00M |
| Pretax income | $3.06B | -$10.25B | $2.58B | $2.08B | $3.64B | $2.43B | $1.65B | $2.17B |
| Income tax | $634.00M | $242.00M | $559.00M | -$105.00M | $589.00M | $468.00M | $334.00M | $385.00M |
| Net income | $2.43B | -$10.50B | $2.02B | $2.18B | $3.05B | $1.96B | $1.31B | $1.78B |
| EBITDA | $3.59B | -$10.30B | $2.68B | $2.07B | $3.42B | $2.57B | $2.33B | $2.55B |
| EPS (basic) | 1.96 | -8.45 | 1.63 | — | 2.46 | 1.57 | 1.06 | — |
| EPS (diluted) | 1.94 | -8.45 | 1.61 | — | 2.43 | 1.56 | 1.04 | — |
| Dividends declared per share | 0.82 | 0.82 | 0.82 | 0.79 | 0.79 | 0.79 | 0.79 | 0.77 |
| Weighted avg. shares (diluted) | 1.25B | 1.24B | 1.25B | — | 1.25B | 1.25B | 1.26B | — |
| Balance sheet | ||||||||
| Cash & equivalents | $6.44B | $3.18B | $7.63B | $7.56B | $7.33B | $5.14B | $7.93B | $9.99B |
| Short-term investments | $0 | $0 | $15.00M | $68.00M | $19.00M | $69.00M | — | $0 |
| Receivables | $5.01B | $5.05B | $4.74B | $4.91B | $5.09B | $4.78B | $4.39B | $4.42B |
| Inventory | $1.90B | $1.95B | $1.91B | $1.77B | $1.78B | $1.82B | $1.76B | $1.71B |
| Current assets | $16.55B | $13.95B | $18.64B | $18.34B | $17.87B | $14.72B | $16.90B | $19.17B |
| PP&E, net | $5.95B | $5.83B | $5.64B | $5.61B | $5.50B | $5.46B | $5.42B | $5.41B |
| Goodwill | $8.31B | $8.31B | $8.31B | $8.31B | $8.31B | $8.31B | $8.31B | $8.31B |
| Intangibles | $13.42B | $14.03B | $16.38B | $16.98B | $17.97B | $18.57B | $19.36B | $19.95B |
| Total assets | $51.41B | $49.36B | $56.28B | $59.02B | $58.53B | $55.72B | $56.43B | $58.99B |
| Current liabilities | $12.00B | $11.02B | $9.48B | $11.81B | $12.30B | $11.19B | $12.34B | $12.00B |
| Short-term debt | $2.42B | $2.41B | $1.31B | $2.81B | $2.81B | $2.81B | $2.81B | $1.81B |
| Long-term debt | $23.82B | $23.83B | $20.86B | $22.13B | $22.14B | $22.14B | $22.15B | $24.90B |
| Total debt | $26.23B | $26.25B | $22.17B | $24.94B | $24.94B | $24.95B | $24.95B | $26.71B |
| Total liabilities | $38.45B | $37.62B | $32.85B | $36.41B | $37.08B | $36.13B | $37.36B | $39.75B |
| Shareholders' equity | $13.04B | $11.83B | $23.52B | $22.70B | $21.54B | $19.67B | $19.16B | $19.33B |
| Net debt | $19.79B | $23.07B | $14.55B | $17.37B | $17.61B | $19.80B | $17.03B | $16.72B |
| Shares outstanding | 1.24B | 1.24B | 1.24B | 1.24B | 1.24B | 1.24B | 1.25B | 1.25B |
| Cash flow statement | ||||||||
| Operating cash flow | $5.04B | $3.57B | $2.54B | $3.33B | $4.11B | $827.00M | $1.76B | $2.98B |
| Capital expenditure | $237.00M | $140.00M | $117.00M | $205.00M | $147.00M | $107.00M | $104.00M | $147.00M |
| Free cash flow | $4.80B | $3.43B | $2.43B | $3.12B | $3.96B | $720.00M | $1.65B | $2.83B |
| Investing cash flow | -$244.00M | -$10.35B | $1.77B | -$1.83B | -$427.00M | -$2.12B | -$415.00M | -$225.00M |
| Financing cash flow | -$1.53B | $2.34B | -$4.24B | -$1.26B | -$1.49B | -$1.57B | -$3.43B | $2.26B |
| Depreciation & amortization | $132.00M | $98.00M | $93.00M | $90.00M | $90.00M | $93.00M | $97.00M | $95.00M |
| Stock-based compensation | $234.00M | $231.00M | $218.00M | $230.00M | $230.00M | $225.00M | $209.00M | $222.00M |
| Dividends paid | $1.04B | $1.03B | $1.04B | $994.00M | $1.00B | $994.00M | $1.01B | $973.00M |
| Share buybacks | $370.00M | $355.00M | $419.00M | $230.00M | $435.00M | $527.00M | $730.00M | $350.00M |
Free plan shows the latest 8 periods; Pro shows all 74 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.